Global Drugs For Vulvovaginal Candidiasis Sales Revenue Is Nearly 770 M USD In 2017
Wednesday, 31 Oct, 2018
In the last several years, global market of Drugs for Vulvovaginal Candidiasis developed steadily, with an average growth rate of 5.5%. In 2017, global sales revenue of Drugs for Vulvovaginal Candidiasis is nearly 770 M USD; the actual sale is about 175 million units.

The classification of Drugs for Vulvovaginal Candidiasis includes Cream, Pessary and other. The proportion of Cream in 2017 is about 47.2%, and the proportion of Pessary in 2017 is about 34.1%. 

The drugs for Vulvovaginal Candidiasis are Miconazole, Clotrimazole, Fluconazole, Econazole and Other, market share of Fluconazole is about 24.5% in 2017.

Drugs for Vulvovaginal Candidiasis is application in Hospital & Clinic and Pharmacy. The most of Drugs for Vulvovaginal Candidiasis is used in Pharmacy, and the market share in 2016 is about 59%. 

Asia-Pacific is the largest consumption place, with a consumption market share nearly 45.5% in 2017. Following Asia-Pacific, North America is the second largest consumption place with the consumption market share of 19.1% in 2017.

Market competition is intense. Bayer, Perrigo, J & J, Pfizer, etc. are the leader of this industry. With the development of society and the changing of consumer demand, the Drugs for Vulvovaginal Candidiasis industry will be more and more popular in the future.